Education, Blood Group Screening, and Identification of Alloimmunization Risk among Pregnant Women as an Early Detection Strategy for Maternal–Neonatal Incompatibility at Gotong Royong Hospital, Surabaya
DOI:
https://doi.org/10.62354/healthcare.v4i2.211Keywords:
ABO and RhD blood groups, antenatal screening, maternal-neonatal incompatibility, pregnant women, red blood cell alloimmunizationAbstract
ABSTRACTBackground: Maternal–neonatal blood group incompatibility may increase the risk of red blood cell alloimmunization and hemolytic disease of the newborn. Objective: This activity aimed to improve pregnant women’s knowledge, determine the distribution of ABO and RhD blood groups, and identify alloimmunization risk at Gotong Royong Hospital, Surabaya. Methods: The activity included education, pre-test and post-test assessments, ABO and RhD blood group testing, and interviews regarding obstetric and transfusion histories among 30 pregnant women. Results: The mean knowledge score increased from 58.3±12.1 to 84.7±8.9. Blood group O was the most common, identified in 12 participants (40.0%). Twenty-nine participants (96.7%) were RhD-positive, while one participant (3.3%) was RhD-negative. Six participants (20.0%) had at least one alloimmunization risk factor. Recommendation: Regular education and screening should be continued, followed by red blood cell antibody testing for at-risk pregnant women.
Downloads
References
1. World Health Organization. WHO Recommendations on Antenatal Care for a Positive Pregnancy Experience. Geneva: World Health Organization; 2016.
2. Regan F, Veale K, Robinson F, Brennand J, Massey E, Qureshi H, et al. Guideline for the investigation and management of red cell antibodies in pregnancy: a British Society for Haematology guideline. Transfus Med. 2025;35(1):3-23. doi:10.1111/tme.13098.
3. American College of Obstetricians and Gynecologists. Practice Bulletin No. 181: Prevention of Rh D alloimmunization. Obstet Gynecol. 2017;130(2):e57-e70. doi:10.1097/AOG.0000000000002232.
4. Moise KJ Jr, Abels EA. Management of red cell alloimmunization in pregnancy. Obstet Gynecol. 2024;144(4):465-480. doi:10.1097/AOG.0000000000005709.
5. Moise KJ Jr, Markham KB, Spinella PC, Sherwood MR, Robinson KA, Wilson LM, et al. A clinical practice guideline for the management of pregnancy alloimmunized to red blood cell antigens. JAMA Netw Open. 2025;8(11):e2544649. doi:10.1001/jamanetworkopen.2025.44649.
6. Christensen RD, Bahr TM, Ilstrup SJ, Dizon-Townson DS. Alloimmune hemolytic disease of the fetus and newborn: genetics, structure, and function of the commonly involved erythrocyte antigens. J Perinatol. 2023;43(12):1459-1467. doi:10.1038/s41372-023-01785-3.
7. de Winter DP, Kaminski A, Tjoa ML, Oepkes D. Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape. BMC Pregnancy Childbirth. 2023;23(1):12. doi:10.1186/s12884-022-05329-z.
8. de Winter DP, Kaminski A, Tjoa ML, Oepkes D, Lopriore E. Hemolytic disease of the fetus and newborn: rapid review of postnatal care and outcomes. BMC Pregnancy Childbirth. 2023;23(1):738. doi:10.1186/s12884-023-06061-y.
9. Sugrue RP, Moise KJ Jr, Federspiel JJ, Abels E, Louie JZ, Chen Z, et al. Maternal red blood cell alloimmunization prevalence in the United States. Blood Adv. 2024;8(16):4311-4319. doi:10.1182/bloodadvances.2023012241.
10. Bollason G, Hjartardottir H, Jonsson T, Gudmundsson S, Kjartansson S, Halldorsdottir AM. Red blood cell alloimmunization in pregnancy during the years 1996-2015 in Iceland: a nationwide population study. Transfusion. 2017;57(11):2578-2585. doi:10.1111/trf.14262.
11. Das S, Shastry S, Rai L, Baliga PB. Frequency and clinical significance of red cell antibodies in pregnancy: a prospective study from India. Indian J Pathol Microbiol. 2020;63(2):241-246. doi:10.4103/IJPM.IJPM_737_19.
12. Wibowo H, Nurrahmah S, Gantini RSE. Maternal IgG in hemolytic disease of the fetus and newborn-ABO incompatibility. Med J Indones. 2024;33(2):70-74. doi:10.13181/mji.oa.247269.
13. Watchko JF. ABO hemolytic disease of the newborn: a need for clarity and consistency in diagnosis. J Perinatol. 2023;43(2):242-247. doi:10.1038/s41372-022-01556-6.
14. Kemper AR, Newman TB, Slaughter JL, Maisels MJ, Watchko JF, Downs SM, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022;150(3):e2022058859. doi:10.1542/peds.2022-058859.
15. de Haas M, Thurik FF, Koelewijn JM, van der Schoot CE. Haemolytic disease of the fetus and newborn. Vox Sang. 2015;109(2):99-113. doi:10.1111/vox.12265.
16. Moise KJ. Red blood cell alloimmunization in pregnancy. Semin Hematol. 2005;42(3):169-178. doi:10.1053/j.seminhematol.2005.04.007.
17. Ghesquière L, Garabedian C, Coulon C, Verpillat P, Rakza T, Wibaut B, et al. Management of red blood cell alloimmunization in pregnancy. J Gynecol Obstet Hum Reprod. 2018;47(5):197-204. doi:10.1016/j.jogoh.2018.02.001.
18. Tormey CA, Hendrickson JE. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood. 2019;133(17):1821-1830. doi:10.1182/blood-2018-08-833962.
19. Mari G, Deter RL, Carpenter RL, Rahman F, Zimmerman R, Moise KJ Jr, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. N Engl J Med. 2000;342(1):9-14. doi:10.1056/NEJM200001063420102.
20. Oepkes D, Seaward PG, Vandenbussche FP, Windrim R, Kingdom J, Beyene J, et al. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med. 2006;355(2):156-164. doi:10.1056/NEJMoa052855.
21. Sainio S, Nupponen I, Kuosmanen M, Aitokallio-Tallberg A, Ekholm E, Halmesmäki E, et al. Diagnosis and treatment of severe hemolytic disease of the fetus and newborn: a 10-year nationwide retrospective study. Acta Obstet Gynecol Scand. 2015;94(4):383-390. doi:10.1111/aogs.12590.
22. Zwiers C, Lindenburg ITM, Klumper FJCM, de Haas M, Oepkes D, van Kamp IL. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus and newborn: the LOTUS study. Am J Obstet Gynecol. 2012;206(2):141.e1-141.e8. doi:10.1016/j.ajog.2011.09.024.
23. Abdelshafi S, Okasha A, Elsirgany S, Khalil A, El-Dessouky S, AbdelHakim N, et al. Peak systolic velocity of the fetal middle cerebral artery to predict anemia in red cell alloimmunization in untransfused and transfused fetuses. Eur J Obstet Gynecol Reprod Biol. 2021;258:437-442. doi:10.1016/j.ejogrb.2021.01.046.
24. Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program. 2015;2015(1):146-151. doi:10.1182/asheducation-2015.1.146.
25. Fasano RM. Hemolytic disease of the fetus and newborn in the molecular era. Semin Fetal Neonatal Med. 2016;21(1):28-34. doi:10.1016/j.siny.2015.10.006.
26. Bennardello F, Coluzzi S, Curciarello G, Todros T, Villa S. Recommendations for the prevention and treatment of haemolytic disease of the fetus and newborn. Blood Transfus. 2015;13(1):109-134. doi:10.2450/2014.0119-14.
27. White J, Qureshi H, Massey E, Needs M, Byrne G, Daniels G, et al. Guideline for blood grouping and red cell antibody testing in pregnancy. Transfus Med. 2016;26(4):246-263. doi:10.1111/tme.12299.
28. Krog GR, Lorenzen H, Clausen FB, Hansen AT, Donneborg ML, Dziegiel MH. ABO haemolytic disease of the newborn: improved prediction by novel integration of causative and protective factors in newborn and mother. Vox Sang. 2022;117(3):415-423. doi:10.1111/vox.13195.
29. Koelewijn JM, Vrijkotte TGM, van der Schoot CE, Bonsel GJ, de Haas M. Effect of screening for red cell antibodies other than anti-D to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion. 2008;48(5):941-952. doi:10.1111/j.1537-2995.2007.01625.x.
30. Murray NA, Roberts IAG. Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2007;92(2):F83-F88. doi:10.1136/adc.2005.076794.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Yustisia Amalia, Miftahul Khairoh, Arkha Rosyaria Badrus
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
-
Open Data Commons Attribution License, http://www.opendatacommons.org/licenses/by/1.0/ (default)
-
Creative Commons CC-Zero Waiver, http://creativecommons.org/publicdomain/zero/1.0/
-
Open Data Commons Public Domain Dedication and Licence, http://www.opendatacommons.org/licenses/pddl/1-0/
